COVID-19
Biosimilars
Cataract Therapeutics
DME
Gene Therapy
Workplace
Ptosis
Optic Relief
Imaging
Geographic Atrophy
AMD
Presbyopia
Ocular Surface Disease
Practice Management
Pediatrics
Surgery
Therapeutics
Optometry
Retina
Cataract
Pharmacy
IOL
Dry Eye
Understanding Antibiotic Resistance
Refractive
Cornea
Glaucoma
OCT
Ocular Allergy
Clinical Diagnosis
Technology

Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy

Name: Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy
Uploaded: 2022-04-23T20:21:00.000Z
Description: Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.

April 23, 2022

Sheryl Stevenson

Video

Conferences|ASCRS

Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.